These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
565 related articles for article (PubMed ID: 32089413)
21. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1. Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457 [TBL] [Abstract][Full Text] [Related]
22. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. Sundar R; Qamra A; Tan ALK; Zhang S; Ng CCY; Teh BT; Lee J; Kim KM; Tan P Gastric Cancer; 2018 Nov; 21(6):1064-1070. PubMed ID: 29915957 [TBL] [Abstract][Full Text] [Related]
23. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332 [TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752 [TBL] [Abstract][Full Text] [Related]
25. Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric Adenocarcinoma. Kim DH; Bae GE; Suh KS; Ryuman D; Song KS; Kim JS; Lee SI; Yeo MK In Vivo; 2020; 34(6):3171-3180. PubMed ID: 33144421 [TBL] [Abstract][Full Text] [Related]
26. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822 [TBL] [Abstract][Full Text] [Related]
27. Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis? Moore A; Hikri E; Goshen-Lago T; Barkan T; Morgenstern S; Brook E; Maderer A; Roth W; Gordon N; Kashtan H; Brenner B; Moehler M; Aharon IB BMC Cancer; 2020 Jan; 20(1):34. PubMed ID: 31937281 [TBL] [Abstract][Full Text] [Related]
28. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991 [TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic Features and Prognostic Significance of Immunohistochemistry and In Situ Hybridization Based Molecular Classification in Gastric Carcinoma. Issin G; Sayar İ; Demir F; Bakkaloğlu İG; Gamsizkan M; Yildiz Z; Yilmaz I; Özmen SA; Çağatay DV; Zemheri IE; Demiriz M; Günal A J Environ Pathol Toxicol Oncol; 2023; 42(4):1-14. PubMed ID: 37522564 [TBL] [Abstract][Full Text] [Related]
30. Reproduction of the Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) Gastric Cancer Molecular Classifications and Their Association with Clinicopathological Characteristics and Overall Survival in Moroccan Patients. Nshizirungu JP; Bennis S; Mellouki I; Sekal M; Benajah DA; Lahmidani N; El Bouhaddouti H; Ibn Majdoub K; Ibrahimi SA; Celeiro SP; Viana-Pereira M; Munari FF; Ribeiro GG; Duval V; Santana I; Reis RM Dis Markers; 2021; 2021():9980410. PubMed ID: 34367379 [TBL] [Abstract][Full Text] [Related]
31. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms. Nakano H; Saito M; Nakajima S; Saito K; Nakayama Y; Kase K; Yamada L; Kanke Y; Hanayama H; Onozawa H; Okayama H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Goto A; Kono K Sci Rep; 2021 Jan; 11(1):1982. PubMed ID: 33479394 [TBL] [Abstract][Full Text] [Related]
32. Impact of programmed death-ligand 1 (PD-L1) positivity on clinical and molecular features of patients with metastatic gastric cancer. Shin M; Ahn S; Jung J; Hyung S; Kim KM; Kim ST; Kang WK; Lee J Cancer Med; 2023 Sep; 12(18):18633-18642. PubMed ID: 37654198 [TBL] [Abstract][Full Text] [Related]
33. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Li Z; Lai Y; Sun L; Zhang X; Liu R; Feng G; Zhou L; Jia L; Huang X; Kang Q; Lin D; Gao J; Shen L Hum Pathol; 2016 Sep; 55():182-9. PubMed ID: 27260946 [TBL] [Abstract][Full Text] [Related]
34. Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. Cho J; Chang YH; Heo YJ; Kim S; Kim NK; Park JO; Kang WK; Lee J; Kim KM ESMO Open; 2018; 3(3):e000326. PubMed ID: 29636988 [TBL] [Abstract][Full Text] [Related]
35. [Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer]. Wang XY; Hu YJ; Dong K; Zhao C; Huang XZ; Lian SY; Sun Y Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1114-1119. PubMed ID: 33152814 [No Abstract] [Full Text] [Related]
36. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. Gu L; Chen M; Guo D; Zhu H; Zhang W; Pan J; Zhong X; Li X; Qian H; Wang X PLoS One; 2017; 12(8):e0182692. PubMed ID: 28796808 [TBL] [Abstract][Full Text] [Related]
37. Human Leukocyte Antigen Class I Deficiency in Gastric Carcinoma: An Adaptive Immune Evasion Strategy Most Common in Microsatellite Instable Tumors. Iwasaki A; Shinozaki-Ushiku A; Kunita A; Yamazawa S; Sato Y; Yamashita H; Fukayama M; Seto Y; Ushiku T Am J Surg Pathol; 2021 Sep; 45(9):1213-1220. PubMed ID: 34310369 [TBL] [Abstract][Full Text] [Related]
38. The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review. Bos J; Groen-van Schooten TS; Brugman CP; Jamaludin FS; van Laarhoven HWM; Derks S Cancer Treat Rev; 2024 Jun; 127():102737. PubMed ID: 38669788 [TBL] [Abstract][Full Text] [Related]
39. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881 [TBL] [Abstract][Full Text] [Related]
40. Programmed death-ligand 1 expression and overall survival in Thai patients with gastric cancer. Chitapanarux T; Gumrai P; Kongkarnka S; Wannasai K; Lertprasertsuke N Sci Rep; 2023 May; 13(1):7241. PubMed ID: 37142693 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]